Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.0 pts less than Nifty Midcap 150 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aurobindo Pharma reported its Q1 FY26 (quarter ended June 30, 2025) unaudited results with strong standalone performance: revenue from operations rose ~15.8% YoY to ₹28,481.7 million, while standalone profit after tax jumped ~70% YoY to ₹5,591.3 million, driven by margin expansion. Consolidated results were more mixed, with revenue up ~4% YoY to ₹78,681.4 million but consolidated PAT declining ~10% YoY to ₹8,242.0 million. The Board declared an interim dividend of ₹4 per share (400%) with a record date of August 8, 2025. The company also announced a definitive agreement to acquire 100% of US-based Lannett Company LLC (subject to regulatory approvals) and incorporated two new step-down subsidiaries during the quarter. Statutory auditor Deloitte Haskins & Sells issued an unmodified (clean) review conclusion.
Strong standalone earnings beat with nearly 70% PAT growth signals improving profitability on the back of better margins, supporting the generous interim dividend. However, softness in consolidated PAT may temper enthusiasm. The Lannett acquisition, if approved, could expand US generics footprint but adds execution and integration risk. Near-term stock reaction likely positive on standalone beat and dividend, with eyes on consolidated trajectory.